Waja-ul-Mafasil is synonomously known as Rheumatoid Arthritis (RA). It is a chronic multi- system disease that affects joints, connective tissues, muscles, tendons and fibrous tissue. It occurs in about 3% of total population in the age group of 20-50 years. Females are three times more affected than males. RA manifests as a symmetric polyarthritis associated with swelling and pain in multiple joints, often initially occurring in the joints of hands and feet. The present study was conducted to evaluate the therapeutic efficacy of Unani pharmacopoeial formulations MajoonSuranjan, SafoofSuranjan and RaughanSuranjan in the management of Waja-ul-Mafasil. These classical Unani drugs significantly reduce joint pain (p<0.05), tenderness (p<0.05), morning stiffness (p<0.05), swelling (p<0.05), movement of restriction (p<0.05), and muscular weakness (p<0.05). The clinical and laboratory findings after treatment have shown that the trial drugs possessed efficacy in the treatment of Waja-ul-Mafasil.

This study demonstrates pronounced anti-arthritic effects indicating that these formulations would be potent drugs for arthritis patients.